Florida Society of Clinical Oncology: Florida Society of Clinical Oncology: The Voice of Oncology in FloridaThe Voice of Oncology in Florida

Biopharmaceutical Organizations:

Marketing

Market Access

Sales

Clinical Liaisons

Medical Affairs

Government Affairs

W ho Should Attend?

Please visit www.FLASCO.org for more information.

Business of Oncology Summit

FLASCO

with the Spring Session &

Annual Meeting

Healthcare Professionals:

Social Workers

Financial Counselors

Patient Advocates

Oncologists

Hematologists

Oncology Physician

Assistants & Nurses

Practice Administrators

Pharmacists

Program Announcement with Agendas

May 11 & 12, 2018

Tampa Marriott Waterside Hotel & Marina 700 South Florida Avenue, Tampa, FL 33602

G ain insight on patient perspectives and what

patient’s find MEANINGFUL in oncology

care. Examine how

VALUE is defined at the

patient, provider, payer,

industry, and national levels. Understand what the

NATIONAL COMPREHENSIVE CANCER

NETWORK learned through the data and usage of

NCCN Value Tools. Hear practical case based

examples of how individual Practices Assess and

Address the wants and needs of Each PATIENT.

What are the effects on the payer, community oncology practices, cancer centers,

hospitals and industry. How can we EMPOWER CANCER PATIENTS?

2018 Business of Oncology2018 Business of Oncology

Meeting Agenda│May 11, 2018Meeting Agenda│May 11, 2018

Barbara L. McAneny, MD, a board-certified medical oncologist/hematologist from Albuquerque, N.M., was elected president-elect of the American Medical Association in June 2017. Dr. McAneny has served on the AMA Board of Trustees since 2010, including as its chair in 2015–2016. An impressive leader, Dr. McAneny has been a member of the American Society of Clinical Oncology (ASCO) Board of Directors, president of the New Mexico Medical Society (NMMS), president of the Greater Albuquerque Medical Association, and president of the New Mexico Chapter of the American College of Physicians.

Barbara McAneny, MD

KEYNOTE SPEAKERS

Reverend Jason Micheli

Jason Micheli, a young father, husband, and pastor, was diagnosed with a bone cancer so rare and deadly that his doctors didn't classify it with one of the normal four stages¬ they simply called it "stage-serious." As Micheli struggled with despair and faced his own mortality, he resolved that although cancer kills the body, it would not kill his spirit, faith, or sense of humor. Micheli knew that the promise of faith makes hope possible. Micheli's story teaches us all how to stay human in dehumanizing situations¬ how to keep living in the face of death.

7:00-8:00 am REGISTRATION & BREAKFAST

8:00-8:55 am

Welcome &

Keynote

Speaker

Including Patients in

the Value Equation.

Thomas Marsland, MD Moderator

Barbara McAneny, MD

President Elect, American Medical Association

9:00-10:00am Oncology

Patient Panel

Patty Rea Moderator

What is meaningful in

oncology care to the

patient?

Lisa Shelar

Patient Name TBD

Caregiver Name TBD

Cynthia Schindele, Benefits Consultant, Lockheed Martin

10:05-10:20am BREAK

10:25-11:00am NCCN and

Value

What have we learned

from NCCN Value

Tools?

Thomas Marsland, MD Moderator

Robert Carlson, MD

National Comprehensive Cancer Network

11:30-12:30pm Patient Centric

Tumor Board

Practical Case Based

Examples of How

Individual Practices

Assess and Address

the Wants and Needs

of Each Patient.

Rick McDonough, MD Moderator

Loretta Loftus, MD, Moffitt

Cancer Center

Michael Diaz, MD, Florida

Cancer Specialists

Randal Henderson, MD, MBA,

University of Florida tentative

Chris Gannon M.D., Memorial

Healthcare System

Nurse Navigator TBD

Cases Presented by:

Cesar Ochoa, MD, Mayo

Clinic Florida

Simon Abi Aad, MD,

University of Miami

Magali Van den Bergh, MD

Moffitt Cancer Center

12:15-1:15pm LUNCH

1:20-2:20pm Pharma Patient

Centric Panel

How is industry

changing to a patient

centric business

model and

philosophy?

Joseph Bailes, MD Moderator

Representative

Genentech

Steve Noga, MD

Takeda Oncology

Representative

Lilly Oncology

Representative

Amgen

Matt Farber

Walgreens

2:25-3:15pm Payer Panel

How are payers

addressing the shift to

patient centric care?

Michael Diaz, MD Moderator

Roger A. Brito, DO,

Aetna Inc.

Bhuvana Sagar, MD

Cigna

Juan Schaening, MD

First Coast Service Options

Representative

Humana

Representative

United Healthcare

3:20 -3:30pm BREAK

3:35 –4:15pm Closing Key

Note Speaker

Empowering Cancer

Patients.

Thomas Marsland, MD Moderator

Reverend Jason Micheli

Author of Cancer is Funny

4:15 –4:30pm OPEN MIC AND ATTENDEE FEEDBACK│ADJOURN

Business of Oncology Summit│Business of Oncology Summit│May 11, 2018May 11, 2018

Patient Centric Oncology Management│Meeting Agenda

YOU, your colleagues, & All Oncology Healthcare

Professionals are invited to attend the

Spring Session Agenda

DON’T MISS!

FLASCO Annual Meeting of Members Saturday, May 12 at 7:30 a.m.

2017 was an EXCITING year for the Florida Society of Clinical Oncology.

Learn why you don’t want to miss out moving FORWARD.

Florida Society of Clinical Oncology: Florida Society of Clinical Oncology: The Voice of Oncology in FloridaThe Voice of Oncology in Florida

Board of Directors

Rick McDonough MD President

Luis Raez MD Vice President

Barry Berman MD Secretary

Maen Hussein MD Treasurer

Michael Diaz MD Immediate Past President

Syed Abid MD Sikander Ailawadhi

Gary Bowers MD Robert Cassell MD PhD

Chakra Chaulagain MD FACP Gerardo Colon-Otero MD

Craig Deligdish MD Dina Dumercy PharmD BCOP

Steven Fein MD Karen Fields MD

Laura Freedman MD Jorge J. Garcia PharmD

Thomas George MD FACP Lucio Gordan MD

Ardeshir Hakam MD MBA William Harrer MD

Eric Harris DO Randal Henderson MD MBA

John Hiemenz MD Hank Hill MD

Mohammad Jahanzeb MD Kun Jiang MD

Waseem Khan MD Kapisthalam Kumar MD

Richard Levine MD Loretta Loftus MD MBA

Reshma Mahtani DO Alan Marks MD

Tarek Mekhail MD MSC FRCSI Joseph Mignone MD

Pareshkumar Patel MD Joseph Rosenblatt MD

Edgardo Santos MD Shalin Shah DO Jason Starr DO

Winston Tan MD Scott Tetreault MD

Gene Wetzstein PharmD BCOP Jonathan Zager MD

Liaison to Board of Directors Ahmed Al-Hazzouri MD

Delmarie Butler RN CBHN Melody Chang RPh

Jose Davila MD Mary Dean MD

Aaron Denson MD Ana Espinosa DNP MBA RN OCN

Shelly Glenn Terry Gruchow PA-C Sachin Kamath MD Jeanelle King PA-C

Mayra Lima MSN ARNP FNP-C Shannon Luker RN OCN CBCN Merry-Jennifer Markham MD

Shahla Masood MD Arjun Mittra MD MBBS

Daniel Morris MD Brendan Prendergast MD

Brian Ramnaraign MD Beau Toskich MD

Teri Valls Magali Van den Bergh MD

Dorothy Phillips

Executive Director

FLASCOFLASCO

LeadershipLeadership 20172017––20182018

FLASCO 2018 SPRING SESSION & ANNUAL MEETING

May 11 & 12, 2018

Friday, May 11, 2018

4:30 – 6:00 pm Poster Presentation

6:00 – 7:30 pm Exhibits and Cash Bar

7:30 – 10:00 pm Dinner and Program ~ Barbara McAneny, MD, CEO AMA President

Elect

Saturday, May 12, 2018

6:30 – 7:30 am Breakfast and Visit Exhibits

7:30 – 8:00 am Rick McDonough, MD Moderator Annual Meeting of Members

8:00 – 9:00 am

Edgardo Santos, MD Moderator Open Spring Session Scientific Discussions

Krishna V. Komanduri, MD Speaking on the topic of Cellular Therapy fo-

cusing on T-cells

9:00 – 9:45 am Break with Exhibitors

10:00 – 11:00

am

Scott Antonia, MD Moderator

Jarushka Naidoo, MD Speaking on the topic of Immunotherapy in Oncology

Upon completion of the conference you will be able to:

1) Understand and implement the patient perspective of meaningful oncology

care.

2) Utilize the NCCN Value tools and learn how they have impacted care to

date.

3) Make decisions that will empower your patients.

4) Discuss the cellular therapy focusing on T-cells.

5) Discuss the immunotherapy treatment in oncology.

6) Utilize information gleaned from industry and payers as they explain the

patient centric business model and philosophy from their perspective.

CONFERENCE OBJECTIVES

THE FLASCO CONFERENCE GOAL THE FLASCO CONFERENCE GOAL is to continue to develop a comprehensive range of

programs that emphasize the latest developments, healthcare policy, state-of-the-art information and enhanced

educational strategies for the intra-professional team.

CONFERENCE OUTCOME MEASURES:CONFERENCE OUTCOME MEASURES:

Participants should be able to apply the knowledge acquired during this Participants should be able to apply the knowledge acquired during this

conference to improve their competence, performance, and/or patient outcomes conference to improve their competence, performance, and/or patient outcomes

in the daily treatment of their patients. To measure attendees perceptions of in the daily treatment of their patients. To measure attendees perceptions of

these gains, they will complete an evaluation form at the end of the conference.these gains, they will complete an evaluation form at the end of the conference.

ACCREDITATION STATEMENTS Physicians: The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

FLASCO has applied for a maximum of 9.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical Educator Consortium and Florida Society of Clinical Oncology. The Medical Educator Consortium is accredited by the ACCME to provide continuing medical education for physicians.

Disclosure Statement:

The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

Nurses and Patient Navigators: Approval for nurses has been applied for by the Southern Florida Chapter of The Leukemia & Lymphoma Society under provider number 50-12996, to award up to 9.0 continuing education contact hours through the Florida Board of Nursing. FLASCO maintains responsibility for this program.

HOTEL RESERVATIONS

Registration Fees for Pharmaceutical Industry Attendees are as follows

for the Business of Oncology on May 11, 2018, 7:00 AM - 4:00 PM:

1 Attendee from Company: $1,000

2 - 4 Attendees from Company: $700 per attendee

5 or more Attendees from Company: $500 per attendee

FLASCO DIAMOND ELITE CORPORATE MEMBERS

ARE ENTITLED TO TWO COMPLIMENTARY ATTENDEE REGISTRATIONS,

FLASCO DIAMOND CORPORATE MEMBERS

ARE ENTITLED TO ONE COMPLIMENTARY ATTENDEE REGISTRATION,

FOR THIS BUSINESS OF ONCOLOGY SUMMIT.

A block of rooms has been reserved at the

Tampa Marriott Waterside Hotel & Marina

700 South Florida Avenue│Tampa, FL 33602

Please make your RESERVATIONS by calling (813) 221-4900 or follow this link

Be sure to mention the Florida Society of Clinical Oncology code word FLASCO Spring

Meetings for meeting rate of $199(plus applicable taxes and hotel fees) per night.

DEADLINE The hotel has requested that all reservations be made prior to April 22, 2018. After that date, reservations will only be accepted on a space and rate available basis.

Page 4 of 4Page 4 of 4

Diamond Elite Amgen

Bristol-Myers Squibb

Merck

Takeda Oncology

Teva Pharmaceuticals

Diamond Astellas

Bayer EMD Serono

Lilly Oncology Sanofi-Genzyme Seattle Genetics

Platinum Adaptive biotechnologies

Eisai

Exelixis

Foundation Medicine

Heron Therapeutics

Oncology Supply/ION Solutions

Puma Biotechnology

Sun Pharma

Walgreens

Gold Gilead Sciences

Silver Biodesix

Clovis Oncology

Helsinn

Kroger Specialty Pharmcy

Novocure

Spectrum

TESARO

REGISTRATION FEES & REGISTRATION FEES &

INFORMATIONINFORMATION

The Board of Directors acknowledges the

following companies as FLASCO Corporate

Members:

As of 1/30/2018

Spring Session Registration is complimentary prior to April 22, 2018 for

FLASCO Regular, Affiliate and Associate Members.

Reminder: To keep your complimentary membership active and in good standing, FLASCO members are encouraged to participate in at least one FLASCO event prior to December 31, 2020.

Level Before or on April 22, 2018 After April 22, 2018

FLASCO Regular Members Complimentary $50.00

FLASCO Affiliate Members Complimentary $50.00

FLASCO Associate Members Complimentary $50.00

FLASCO Courtesy Members $200.00 $250.00

Non-FLASCO Members $250.00 $300.00

*FLASCO reserves the right to alter this program without prior notice. Speakers and agenda are subject to change.